Note 7 - Commitments and Contingencies (Details Textual) - USD ($) |
1 Months Ended | 3 Months Ended | 12 Months Ended | |||
|---|---|---|---|---|---|---|
Mar. 19, 2024 |
Mar. 12, 2024 |
Jan. 31, 2025 |
Mar. 31, 2024 |
Dec. 31, 2024 |
Dec. 31, 2023 |
|
| Stock Issued During Period, Shares, New Issues | 262,501 | 262,501 | ||||
| Certain Claims Arising From an Interpretation of Certain Rights of SPA [Member] | ||||||
| Stock Issued During Period, Shares, New Issues | 500,000 | 500,000 | 760,000 | |||
| Shares Issued, Price Per Share (in dollars per share) | $ 1.85 | |||||
| Stock Issued During Period, Value, New Issues | $ 924,000 | |||||
| Litigation Settlement, Fee Expense | $ 164,000 | |||||
| X | ||||||||||
- Definition Amount of litigation expense, including but not limited to legal, forensic, accounting, and investigative fees. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Definition Per share or per unit amount of equity securities issued. No definition available.
|
| X | ||||||||||
- Definition Number of new stock issued during the period. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Details
|